MindImmune Closes $10.2M Series A Extension to Advance First-in-Class Alzheimer’s Therapeutic

MindImmune Therapeutics, a private company developing new treatments targeting the inflammatory drivers of neurodegenerative disease, announced two major...

November 25, 2025 | Tuesday | News
BriaPro Launches AI-Driven Collaboration With Receptor.AI to Design Isoform-Selective Anti-Cancer Kinase Inhibitors

Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partners...

November 21, 2025 | Friday | News
NeuroThera Labs and Clearmind File Israeli Patent for Novel MEAI–PEA Combination Therapy Targeting Depression

SciSparc Ltd. announced that NeuroThera Labs Inc. , a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous sy...

November 21, 2025 | Friday | News
Dexcom Receives FDA Clearance for Smart Basal, a First-of-Its-Kind AI-Powered Basal Insulin Dosing Solution

-DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-int...

November 20, 2025 | Thursday | News
PrognomiQ Launches ProVue Lung, a Blood-Based Test Designed for Earlier Lung Cancer Detection

Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network –  Pr...

November 19, 2025 | Wednesday | News
Ankyra Therapeutics Doses First Patient in Phase 1b LANTERN Trial Evaluating Tolododekin Alfa With PD-1/PD-L1 Checkpoint Inhibitors in NSCLC

Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint bl...

November 18, 2025 | Tuesday | News
Thermo Fisher Scientific Enrolls First Patient in New PPD™ CorEvitas™ Myasthenia Gravis Registry

  Thermo Fisher Scientific Inc., the world leader in serving science, announced the enrollment of the first patient in the new PPD™ CorEvitas&t...

November 18, 2025 | Tuesday | News
Scotland Strengthens Position as Global Brain Health Innovator With New Alzheimer’s Research Centre in Aberdeen

Aberdeen clinical research centre widens access to clinical trials across Scotland, advancing early Alzheimer’s research ONE BioHub provides Scott...

November 18, 2025 | Tuesday | News
AtomVie and Ariceum Achieve First Clinical Dosing of 225Ac-SSO110 in SANTANA-225 Trial

  AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum The...

November 13, 2025 | Thursday | News
GenomOncology Technology Enables Rapid Launch of Glioblastoma Foundation Genomic Testing Lab

GenomOncology announced a strategic partnership with the Glioblastoma Foundation to transform genomic testing for the nation's most aggressive brain canc...

November 12, 2025 | Wednesday | News
Vascarta and CUNY Report Preclinical Breakthrough Demonstrating STO-1 Selectively Eliminates Glioblastoma Cells

Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...

November 11, 2025 | Tuesday | News
Boehringer Ingelheim Receives FDA National Priority Voucher for HERNEXEOS® in First-Line HER2-Mutant NSCLC

  The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets...

November 10, 2025 | Monday | News
SanegeneBio and Eli Lilly Announce Global Collaboration on RNAi Therapies for Metabolic Diseases

  SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collab...

November 10, 2025 | Monday | News
Dupixent Delivers First Positive Phase 3 Results in Allergic Fungal Rhinosinusitis

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal cong...

November 10, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close